FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer

    NEXT STORY
    AveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
    PREV STORY
    Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Worldwide Hematology Drugs Industry to 2030 – Players Include Novo Nordisk, Shire and Bayer Among Others

    author_avatar
    NASDAQ Market News

    International Society for Quality in Health Care (ISQua): “Healthcare systems must adapt to cope with escalating impact of ageing populations” says President of leading global healthcare organization

    DUBLIN, Ireland, Oct. 16, 2016 (GLOBE NEWSWIRE) -- Professor Clifford Hughes was speaking in ...

    author_avatar
    NASDAQ Market News

    Epistem completes board line up and launches new NGS service

    MANCHESTER, United Kingdom, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Epistem Limited, the Manchester based ...

    author_avatar
    NASDAQ Market News